Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01499355 · ClinicalTrials.gov registry record · Phase 2
BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 276
- Enrollment target
NCT01499355 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 276 participants.
The verdict
NCT01499355, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 276 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the efficacy of BIIB023 as an add-on treatment to background therapy compared with placebo in combination with background therapy in the treatment of participants with active, biopsy-proven lupus nephritis. The secondary objectives of this study are to assess the safety and tolerability of BIIB023 compared with placebo in this study population.
Interventions
- BIOLOGICAL Placebo
- DRUG mycophenolate mofetil
- DRUG oral corticosteroids
- BIOLOGICAL BIIB023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01499355
The ClinicalTrials.gov registry entry for NCT01499355 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01499355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01499355 about?
NCT01499355 is a clinical study titled "BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis". The primary objective of the study is to assess the efficacy of BIIB023 as an add-on treatment to background therapy compared with placebo in combination with background therapy in the treatment of participants with active, biopsy-proven lupus nephritis. The secondary objectives of this study are to...
What is the current status of trial NCT01499355?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 276 participants. The study started on 2012-07. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01499355?
The interventions under investigation include: Placebo (BIOLOGICAL), mycophenolate mofetil (DRUG), oral corticosteroids (DRUG), BIIB023 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01499355?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.